post core revenu growth line expect beat ep
continu area potenti concern ms us pharma appli given subdu
sentiment print good enough expect appear reason
convict upsid still view floor/attract entri point
given buyback l-t outlook price-to-earnings
revenu growth dead forecast consensu guidanc
overal revenu forecast entir due fx
growth driven better expect ta result water divis
core revenu growth light forecast due continu mass spec
weak posit includ china growth mid-teen continu strong
recur revenu growth y/i area weaker expect result
includ pharma industri us y/i favor
comparison page full detail
gross margin y/i ahead forecast ahead
consensu appear mostli function revenu mix higher recur
ta mix slight fx tailwind oper expens dead expect
accordingli oper margin beat vs driven gross
margin non-oper item larg expect accordingli gross margin drove
ep beat high end guidanc rang
manag reiter y/i constant currenc revenu growth guidanc
impli core growth though model still arriv
midpoint ep guidanc ep guidanc reduc midpoint
due fx expect repres y/
revenu growth tailwind prior guidanc y/i reduc
ep forecast due fx alter underli expect outsid fx
though note like remain upsid share count forecast via buyback
continu believ still like well posit grow revenu mid-singl
digit long term best-in-class margin cash flow attract long-term
fundament outlook plu plan buy back current market cap stock
next year limit downsid howev without strong convict
revenu growth exceed consensu still high absolut multipl price-to-earnings
albeit palat price-to-earnings premium see urgenc purchas share today
worth note setup could improv next month new
product follow need maintain price target base dcf
pleas see page report import disclosur
water remain one top life scienc tool compani fundament basi
compani post growth sever consecut year growth outlook
remain bright pharma appli market hope next sever year rate
share market perform price target base dcf analysi repres
price-to-earnings premium peer multipl
pharma grow msd
revenu grow drive
end market condit remain
grow organ
dd ep growth
higher expect oper leverag
growth sustain
great cash flow return profil
macroeconom competit
current expect
oper leverag lower level
anoth period slower expect
growth caus investor revisit
inher growth rate compani
corpor analyt instrument manufactur
divis design manufactur sell servic high-perform liquid
chromatographi hplc ultra perform liquid chromatographi uplc togeth
hplc refer lc mass spectrometri ms instrument system support
product includ chromatographi column consum product post-
warranti servic plan ta divis ta compani primarili design
manufactur sell servic thermal analysi rheometri calorimetri instrument
compani also develop supplier software-bas product interfac
compani instrument well manufactur instrument
compani report thomson eikon cowen compani
cowen vs consensu mm except cc fx y/i cc growth fx y/ygross re-affirmed oper fx tailwind select revenu metric mm except statement mm except currenc per count ep came ahead consensu expect higher expect tax rate off-set lower expect non-oper item share count ep beat larg driven gross water divis revenu came forecast constant currenc growth y/i forecast rel forecast recur revenu growth hsd y/i line expect water divis instrument flat y/i vs y/i growth forecast end market pharma grew y/i industri y/i acc/gov y/i geographi asia grew y/i strong growth china europ grew y/i us declin ta revenu came ahead expect constant currenc growth y/i ahead expect streetaccount consensu revenu came expect entir delta due fx constant currenc revenu growth y/i line expect though consensu rel expect ta acc/gov much better expect off-set weaker expect us water divis instrument result line quarter compon perform unlik garner much excit pharma growth gross margin came better expect consensu gross margin aid product mix quarter higher recur mix higher ta mix came slightli ahead expect manag continu priorit sg came slightli oper margin came forecast driven entir better expect gross margin tax rate forecast off-set better expect non-oper expens cowen
compani report cowen compani
mm except per share cagrcommentstot cc re-affirmed fx y/i cc growth fx currenc ex food growth impact y/i y/i impact cowen
compani report thomson eikon cowen compani
mm except cagrcommentsnet cc re-affirmed fx y/i cc growth fx y/yorgan currenc re-affirmed leverag sg grown revenu oper growth sale growth re-affirmed non-oper interest re-affirmed tax earn per fx dilut share count re-affirmed assum cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk upsid includ limit recoveri macroeconom condit
increas client budget demand lc/m instrument consum better
expect product innov associ revenu contribut share gain risk
downsid includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc juli et dissemin juli et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
